Gainers
- Klotho Neurosciences KLTO stock moved upwards by 20.3% to $2.19 during Monday's after-market session. The company's market cap stands at $71.1 million.
- Kairos Pharma KAPA shares increased by 15.07% to $0.65. The market value of their outstanding shares is at $10.9 million.
- Venus Concept VERO shares increased by 12.5% to $3.15. The company's market cap stands at $4.4 million.
- CollPlant Biotechnologies CLGN shares increased by 8.09% to $1.87. The company's market cap stands at $21.4 million.
- AquaBounty Techs AQB shares moved upwards by 7.89% to $0.82. The company's market cap stands at $3.1 million.
- NuCana NCNA shares rose 6.69% to $0.08.
Losers
- Citius Pharmaceuticals CTXR stock fell 13.9% to $1.18 during Monday's after-market session. The market value of their outstanding shares is at $12.1 million.
- AirSculpt Technologies AIRS shares decreased by 12.68% to $4.41. The company's market cap stands at $259.2 million.
- BioAtla BCAB stock decreased by 9.1% to $0.45. The company's market cap stands at $26.5 million.
- TELA Bio TELA stock fell 8.38% to $1.75. The company's market cap stands at $69.2 million.
- Intensity Therapeutics INTS stock declined by 7.3% to $0.46. The company's market cap stands at $8.4 million.
- Athira Pharma ATHA shares declined by 6.38% to $0.31. The company's market cap stands at $12.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
AIRSAirSculpt Technologies Inc
$6.443.21%
Edge Rankings
Momentum
87.49
Growth
9.59
Quality
N/A
Value
29.65
Price Trend
Short
Medium
Long
AQBAquaBounty Technologies Inc
$0.75461.97%
ATHAAthira Pharma Inc
$0.3800-4.55%
BCABBioAtla Inc
$0.3612-0.80%
CLGNCollPlant Biotechnologies Ltd
$2.796.90%
CTXRCitius Pharmaceuticals Inc
$1.374.58%
INTSIntensity Therapeutics Inc
$0.30732.95%
KAPAKairos Pharma Ltd
$1.18-4.84%
KLTOKlotho Neurosciences Inc
$0.78240.44%
NCNANuCana PLC
$4.12-0.72%
TELATELA Bio Inc
$1.631.87%
VEROVenus Concept Inc
$2.470.82%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.